OverviewSuggest Edit

Agios Pharmaceuticals is a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases.

Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. The Company intends to apply its deep understanding of metabolism, coupled with its ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.

Agios also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The Company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases.

TypePublic
Founded2008
HQCambridge, MA, US
Websiteagios.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Dec 2019)536(+12%)
Job Openings34
Revenue (FY, 2020)$203.2 M(+73%)
Share Price (Oct 2021)$48.5(+2%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Agios Pharmaceuticals

Jacqualyn Fouse

Jacqualyn Fouse

Chief Executive Officer, Director
Jonathan Biller

Jonathan Biller

Chief Financial Officer and Head of Legal and Corporate Affairs
Shin-San Michael Su

Shin-San Michael Su

Co-Founder and Advisor
Bruce Car

Bruce Car

Chief Scientific Officer
Melissa McLaughlin

Melissa McLaughlin

Chief People Officer
Darrin Miles

Darrin Miles

Chief Commercial Officer
Show more

Agios Pharmaceuticals Office Locations

Agios Pharmaceuticals has an office in Cambridge
Cambridge, MA, US (HQ)
88 Sidney St
Show all (1)

Agios Pharmaceuticals Financials and Metrics

Agios Pharmaceuticals Revenue

Agios Pharmaceuticals's revenue was reported to be $203.2 m in FY, 2020
USD

Net income (Q1, 2021)

1.9b

EBIT (Q1, 2021)

(91.2m)

Market capitalization (22-Oct-2021)

3.0b

Closing stock price (22-Oct-2021)

48.5

Cash (31-Mar-2021)

1.9b

EV

1.2b
Agios Pharmaceuticals's current market capitalization is $3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

25.5m65.4m43.0m94.4m117.9m203.2m

Revenue growth, %

156%(10%)18%

Cost of goods sold

1.4m1.3m2.8m

Gross profit

93.0m116.6m200.4m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

6.3m6.3m8.4m8.4m11.3m11.4m8.8m49.2m15.2m30.2m13.7m17.4m87.1m27.6m31.7m

Cost of goods sold

695.0k334.0k533.0k

Gross profit

14.5m29.9m86.6m

Gross profit Margin, %

95%99%99%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

71.6m14.0m71.8m160.8m102.7m70.5m80.9m127.4m

Accounts Receivable

2.3m3.4m600.0k169.0k5.1m

Prepaid Expenses

2.5m4.8m8.7m17.5m24.2m23.7m

Inventories

10.3m869.0k7.3m14.7m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

77.5m106.0m32.8m108.2m70.0m35.3m72.5m80.0m39.0m234.0m285.5m200.3m138.7m132.7m364.5m210.3m156.5m103.4m83.6m81.7m89.1m295.9m104.9m1.9b

Accounts Receivable

6.9m5.3m3.0m571.0k2.0m3.4m3.5m779.0k859.0k2.6m

Prepaid Expenses

2.0m2.6m3.0m2.8m5.0m5.5m4.6m7.2m9.2m8.9m10.3m12.4m13.0m15.3m15.6m19.7m19.1m20.0m29.2m27.0m28.9m19.5m

Inventories

863.0k2.3m4.7m5.8m9.8m11.2m11.4m
USDQ2, 2013

Financial Leverage

-1.3 x
Show all financial metrics

Agios Pharmaceuticals Online and Social Media Presence

Embed Graph

Agios Pharmaceuticals News and Updates

Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGIO, CLVS, AQMS, COCP, and LAZR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

FDA approves Agios Pharmaceuticals leukemia drug

Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator.

Agios Pharmaceuticals Blogs

Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021

Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021 Content Import Thu, 10/21/2021 - 16:02 Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021 Oct 21, 2021 This release is a backfill fr…

Agios at 2021 Cantor Virtual Global Healthcare Conference

Agios at 2021 Cantor Virtual Global Healthcare Conference James.Jordan@n… Mon, 08/30/2021 - 09:33 Agios at 2021 Cantor Virtual Global Healthcare Conference Display "add to calendar" true Event Type Conference Presentation Clic…

Agios at Citi’s 16th Annual Biopharma Virtual Conference: Benign Hematology Panel Discussion

Agios at Citi’s 16th Annual Biopharma Virtual Conference: Benign Hematology Panel Discussion James.Jordan@n… Mon, 08/30/2021 - 09:32 Agios at Citi’s 16th Annual Biopharma Virtual Conference: Benign Hematology Panel Discussion Display "add to calendar" true Eve…

Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

-- PDUFA Date Set for February 17, 2022 -- CAMBRIDGE, Mass. , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that the U.S.

Q1 2021 Agios Pharmaceuticals Inc Earnings Conference Call

Q1 2021 Agios Pharmaceuticals Inc Earnings Conference Call James.Jordan@n… Wed, 04/07/2021 - 10:46 Q1 2021 Agios Pharmaceuticals Inc Earnings Conference Call Display "add to calendar" true Event Type Earnings Conference Call …

Agios Shareholders Approve Sale of Oncology Business to Servier

Agios Shareholders Approve Sale of Oncology Business to Servier Content Import Thu, 03/25/2021 - 16:01 Agios Shareholders Approve Sale of Oncology Business to Servier Mar 25, 2021 This release is a backfill from a News Wire General C…
Show more

Agios Pharmaceuticals Frequently Asked Questions

  • When was Agios Pharmaceuticals founded?

    Agios Pharmaceuticals was founded in 2008.

  • Who are Agios Pharmaceuticals key executives?

    Agios Pharmaceuticals's key executives are Jacqualyn Fouse, Jonathan Biller and Shin-San Michael Su.

  • How many employees does Agios Pharmaceuticals have?

    Agios Pharmaceuticals has 536 employees.

  • What is Agios Pharmaceuticals revenue?

    Latest Agios Pharmaceuticals annual revenue is $203.2 m.

  • What is Agios Pharmaceuticals revenue per employee?

    Latest Agios Pharmaceuticals revenue per employee is $379.1 k.

  • Who are Agios Pharmaceuticals competitors?

    Competitors of Agios Pharmaceuticals include Forbius, Courier Therapeutics and Olema Oncology.

  • Where is Agios Pharmaceuticals headquarters?

    Agios Pharmaceuticals headquarters is located at 88 Sidney St, Cambridge.

  • Where are Agios Pharmaceuticals offices?

    Agios Pharmaceuticals has an office in Cambridge.

  • How many offices does Agios Pharmaceuticals have?

    Agios Pharmaceuticals has 1 office.